Ilya Rachman

Chief Executive Officer at IMMIX BIOPHARMA, INC.

Net worth: 3 M $ as of 30/03/2024

52 year

Consumer Services

Health Technology

Profile

Ilya Rachman is a Chairman & Chief Executive Officer and founder of Immix Biopharma, Inc. which is founded in 2012.
He is also currently an Executive Chairman at Nexcella, Inc. Dr. Rachman has an MBA from the University of California, Los Angeles, a graduate and doctorate degree from the University of Illinois, and an undergraduate degree from the University of Iowa.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
IMMIX BIOPHARMA, INC. 3.53%	13/08/2023	902,500 ( 3.53% )	3 M $	30/03/2024

Ilya Rachman active positions

Companies	Position	Start
IMMIX BIOPHARMA, INC.	Chief Executive Officer	31/12/2011
Nexcella, Inc. Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned.	Chairman	-

All active positions of Ilya Rachman

Training of Ilya Rachman

University of California, Los Angeles	Masters Business Admin
University of Illinois	Doctorate Degree
University of Iowa	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ilya Rachman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Immix Biopharma, Inc.
Nexcella, Inc. Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned.	Health Technology